vonafexor
Selected indexed studies
- New mechanistic understanding of FXR agonist Vonafexor: inducing sublethal damage of HBV-positive liver cancer cells via promoting anti-tumor immunity. (Br J Cancer, 2025) [PMID:40588513]
- Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. (J Hepatol, 2023) [PMID:36334688]
- A novel in vitro system for simultaneous infections with hepatitis B, C, D and E viruses. (JHEP Rep, 2025) [PMID:40242313]
_Worker-drafted node — pending editorial review._
Connections
vonafexor is a side effect of
Sources
- New mechanistic understanding of FXR agonist Vonafexor: inducing sublethal damage of HBV-positive liver cancer cells via promoting anti-tumor immunity. (2025) pubmed
- Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. (2023) pubmed
- A novel in vitro system for simultaneous infections with hepatitis B, C, D and E viruses. (2025) pubmed
- Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. (2021) pubmed
- Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders. (2025) pubmed
- From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome. (2026) pubmed
- Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach. (2023) pubmed